Palumbo Vincenzo Davide, Romeo Marcello, Marino Gammazza Antonella, Carini Francesco, Damiani Provvidenza, Damiano Giuseppe, Buscemi Salvatore, Lo Monte Attilio Ignazio, Gerges-Geagea Alice, Jurjus Abdo, Tomasello Giovanni
Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy.
Department of Surgical, Oncological and Stomatological Disciplines, School of Medicine, University of Palermo, Palermo, Italy.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Sep;160(3):372-7. doi: 10.5507/bp.2016.044. Epub 2016 Sep 13.
Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity.
Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index.
All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment.
A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.
肠道菌群失调似乎是炎症性肠病的主要病因，而益生菌似乎是预防其发生的合适支持手段。实际上，益生菌组合和抗炎药物是对抗炎症性肠病的一种武器。本研究评估联合治疗（美沙拉嗪加唾液乳杆菌、嗜酸乳杆菌和双歧杆菌BGN4菌株的益生菌组合）对溃疡性结肠炎活动期的长期（2年）影响。
招募60例中重度溃疡性结肠炎患者：其中30例患者每日口服1200毫克美沙拉嗪；30例患者每日口服1200毫克美沙拉嗪，并每日两次服用唾液乳杆菌、嗜酸乳杆菌和双歧杆菌BGN4菌株的益生菌组合。治疗持续两年，并根据改良的梅奥疾病活动指数评估临床反应。
与对照组相比，所有接受联合治疗的患者均有更好的改善。特别是，即使在治疗两年后，益生菌的有益效果仍很明显。
抗炎药物和益生菌的长期治疗方式是可行的，并且在轻度至中度溃疡性结肠炎中可能是皮质类固醇的替代疗法。
